Testing effectiveness (Phase 2)Study completedNCT03520920
What this trial is testing
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
Who this might be right for
Marginal Zone LymphomaFollicular LymphomaDiffuse Large B-Cell Lymphoma
BeiGene 41